solute carrier family 6 member 10, pseudogeneGenealiases: []
Q-omics provides the consensus-scored SLC6A10P profile across patient tissues and cancer cell-line models. SLC6A10P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SLC6A10P is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, SLC6A10P RNA expression shows 9,294 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where SLC6A10P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC6A10P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC6A10P survival associations across molecular data types. SLC6A10P RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC6A10P RNA expression–survival associations across cancer types. High SLC6A10P expression shows unfavorable associations in KIRP, UCEC and LUAD, but favorable associations in UVM, READ and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SLC6A10P RNA expression.
This table summarizes SLC6A10P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC6A10P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC6A10P shows lower tumor expression in COAD and higher tumor expression in KIRC, LUSC, KICH, HNSC and BRCA. The KIRC box plot shows higher SLC6A10P RNA expression in tumor versus normal tissue (log2 FC = +0.036, t-test p < 0.001).
This table shows molecular features associated with SLC6A10P in patient tissues and cancer cell lines. In patient samples, SLC6A10P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC6A10P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS.
